This clinical trial is focused on studying Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The study is investigating the effectiveness of a combination of treatments, including Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone. Elotuzumab is a monoclonal antibody, which is a type of protein designed to target specific cells, while Carfilzomib is a medication that helps to stop the growth of cancer cells. Lenalidomide is an immunomodulating agent, meaning it helps to regulate the immune system, and Dexamethasone is a steroid that reduces inflammation and suppresses the immune system.
The purpose of this study is to compare the effectiveness of two different treatment regimens in patients who have been newly diagnosed with Multiple Myeloma. One group will receive a combination of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone, while the other group will receive Carfilzomib, Lenalidomide, and Dexamethasone without Elotuzumab. The study will also look at how well patients do after receiving an autologous stem cell transplant, which is a procedure where a patient’s own stem cells are used to replace damaged or destroyed bone marrow.
Participants in the study will receive treatment over a period of time and will be monitored to see how their disease responds. The study will also assess the long-term effects of the treatments, including how long patients remain free from disease progression. This research aims to improve understanding of how these treatments can be used to manage Multiple Myeloma and to determine the best approach for maintaining health after initial treatment.
Austria 
Germany 
